The Hippo pathway is an inhibitor of adult heart regeneration; if you take the Hippo pathway away, then the heart can regenerate. But, can the Hippo pathway also play a role in the embryonic development of the heart?
In his laboratory at Baylor College of Medicine, Dr. James Martin, professor of molecular physiology and biophysics and Vivian L. Smith Chair in Regenerative Medicine, and his colleagues study the molecular mechanisms controlling cell growth and differentiation in embryogenesis and their relation to congenital heart defects and heart muscle regeneration.
One of their investigations explored the role the Hippo pathway plays in regulating the development of a group of cardiac progenitor cells called epicardial cells. During development and heart injury, these cells become essential supporters of the cardiomyocytes, the beating muscle cells of the heart.
The researchers genetically engineered mice to lack two essential components of the Hippo pathway, and then compared these hearts’ development with that of normal hearts. Martin and his colleagues looked at the structure of the heart blood vessels and also analyzed nearly 18,200 cells taken from heart tissue during a period of development.
The Hippo pathway is essential for normal heart development
The hearts of the mice with a defective Hippo pathway were smaller than normal hearts. Unexpectedly, blood vessel development was also defective; blood vessel coverage was reduced and less dense. These and other results suggested that the Hippo pathway is required for normal heart and blood vessel development.
“In addition, we analyzed thousands of cells from developing heart tissue with a technology called single cell transcriptomics that provides a ‘high-resolution view’ of the status of individual cells,” said Martin, who also is director of the Cardiomyocyte Renewal Lab at the Texas Heart Institute. “For instance, we learned what genes were turned on and what molecules the cells were expressing. This high level of detail shed light into the cellular and molecular processes leading to an adult heart and how they are coordinated.”
The researchers learned of a number of genes and pathways they had not thought would be linked to the Hippo pathway during the heart’s embryonic development, for instance, the retinoic acid or vitamin A pathway. They also discovered that when the Hippo pathway is defective during the heart’s embryonic development, cardiac fibroblasts do not advance through their normal developmental program.
“We found cells suspended in intermediate states and producing factors important for regulating growth and proliferation of vascular endothelial cells,” Martin said. “That was all unexpected.”
These new insights suggest that during heart development, when cells progress through transition states, the Hippo pathway regulates the production of factors that regulate normal growth of vascular endothelial cells. Importantly, the Hippo pathway plays an essential role in this process, much like an orchestra director coordinating the development of several types of cells in the heart.
“We know that the Hippo pathway is involved in regeneration of the adult heart, but also controls the size of the developing heart,” Martin said. “As the heart grows, more vascular cells need to move into the heart to provide blood vessels to sustain its growth and later support the function of the adult heart. We think that the Hippo pathway can sense the size of the growing heart and, by regulating a number of secreted factors, determine how many cardiac fibroblasts and endothelial cells develop in the heart.”
Martin and his colleagues are applying these findings to better understand regeneration of the adult heart.
If we can figure out ways to improve the blood vessels’ ability to regenerate in the adult heart, we would open new possibilities to improve the treatment of heart disease in the future,” Martin said.
Find out all the details of this work in the journal Developmental Cell.
Other contributors to this work include Yang Xiao, Matthew C. Hill, Min Zhang, Thomas J. Martin, Yuka Morikawa, Suya Wang, Alexander R. Moise and Joshua D. Wythe. The authors are affiliated with one of more of the following institutions: Baylor College of Medicine, Texas Heart Institute, Texas A&M Health Science Center, Shanghai Children’s Medical Center, University of Kansas and Northern Ontario School of Medicine.
This project was supported in part by an Intellectual and Developmental Disability Research Center grant (1U54 HD083092) from the Eunice Kennedy Shriver National 557 Institute of Child Health & Human Development; the Mouse Phenotyping Core at Baylor College of Medicine with funding from the National Institutes of Health (U54 HG006348) and grants from the National Institutes of Health (DE 023177, HL 127717, HL 130804, HL 118761, HD 077260, F31HL136065 and the Vivian L. Smith Foundation. Other support included institutional startup funds from the CVRI at Baylor College of Medicine, the AHA (16GRNT31330023), the Transatlantic Network of Excellence Award LeDucq Foundation Transatlantic Networks of Excellence in Cardiovascular Research 14CVD01: “Defining the genomic topology of atrial fibrillation.”